09:16 AM EDT, 06/03/2024 (MT Newswires) -- Moderna ( MRNA ) and Merck ( MRK ) said Monday that results from the phase 2b clinical trial assessing mRNA-4157 (V940) plus Merck's ( MRK ) Keytruda in patients with resected high-risk melanoma after complete resection showed sustained improvement in recurrence-free survival, the study's primary endpoint.

The companies said that with a median follow-up of about three years, the combination therapy cut the risk of recurrence or death by 49% compared with Keytruda alone.

The combination therapy also continued to show improved distant metastasis-free survival, a secondary endpoint of the study, lowering the risk of developing distant metastasis or death by 62% compared with Keytruda alone, according to the companies.

Price: 140.23, Change: -2.32, Percent Change: -1.63